IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the ...

Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the ...

Ku itariki ya mbere y'uku kwezi, 'drone' zirenga 100 za Ukraine zarashe ku ndege z'intambara z'Uburusiya zari ku bibuga biri ...

Byatangajwe ko abantu 12 bishwe muri Ukraine, igisirikare cyayo kirwanira mu kirere kivuga ko ahantu 22 hibasiwe n'ibitero ...

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized ...

At this year's ASCO meeting, IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma ...

A Phase 1/2 clinical study of PD-1/IL-2 α-bia s bispecific antibody fusion protein (IBI363) in the treatment of advanced "cold" tumor subtypes (acral and mucosal) malignant melanoma The data presented ...

SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...

SAN JOSE, Occidental Mindoro (PIA) — Agriculture Secretary Francisco Tiu Laurel Jr. announced the construction of a ...

The data presented is from a Phase 1/2 clinical study (NCT05636215) aimed at evaluating the safety, tolerability, and preliminary efficacy of IBI354 in participants with advanced solid tumors. As of ...